We report the synthesis and in vitro activity against T. cruzi epimastigotes of 15 novel quinoxaline derivatives. Ten of the derivatives presented IC 50 values lower than the reference drugs Nfx and Bzn; four of them standed out with IC 50 values lower than 1.5 M. Moreover, unspecific cytotoxicity and genotoxicity studies are also reported. Compound 14 showed a SI higher than 24, whereas compound 10 was the only one that was negative in the genotoxicity screening.
more than 25 million people are at risk of infection.
CD is curable if treatment is initiated soon after infection; therefore, access to diagnosis is essential. If not treated, 30% of the affected people develop heart damage and 10%
suffer from digestive and/or neurological alterations. Nifurtimox (Lampit®) and Benznidazol (Rochagan®) are the only available drugs for CD and they were developed more than 40 years ago. Neither of them is approved by the FDA. 5 The major limitation of currently available drugs is their lower antiparasitic activity in the established chronic form of the disease, which is the most prevalent presentation. On the other hand, both drugs have undesired side effects that can lead to treatment discontinuation, which for Nfx include anorexia, nausea and vomiting causing severe weight loss, insomnia and irritability, while for Bnz the most common adverse effect is urticarial dermatitis. 6, 7 Three clinical trials have recently been conducted. A phase II proof-of-activity study of oral posaconazole in the treatment of asymptomatic chronic CD was completed in January 2015 and no conclusions have been reported. 8 The phase II clinical trial for the treatment of chronic CD with posaconazole and benznidazole (CHAGASAZOL) and a higher treatment failure was observed in patients in the posaconazole groups than in the Bnz group. 9, 10 Finally, a proof-of-concept study of the promising NCE E1224 was recently completed but the development of E1224 as monotherapy has been stopped and it will be considered for new combinatory regimens. 5, 11, 12 This background justifies the urgent need for novel and better drugs to treat both acute and chronic phases. Quinoxaline derivatives are a chemical scaffold that has showed a wide spectrum of biological activities. 13 Our group has vast experience in the synthesis and biological evaluation of quinoxaline derivatives with anti-cancer, antimycobacterium and anti-inflammatory activities among others. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] One of the projects has been focused on the study of novel quinoxaline derivatives as anti T. cruzi agents. In this field, over 200 derivatives have been prepared and evaluated as anti-trypanosomatid agents and some structural requirements have been established for their anti-chagasic in vitro activity. 20, 25, 27, 28 Therefore, it can be considered that the main structural N,N-DMF was substituted by acetonitrile that could be used as aprotic polar solvent that would avoid the aforementioned difficulties. [39] [40] [41] Finally, triethylamine was used as base and 6 compounds were prepared using these conditions (5, 6, 8-11) . All of the compounds were fully characterized by infrared spectroscopy, nuclear magnetic resonance and elemental microanalyses (See Supplementary material).
Compounds were assayed against the epimastigote form of T. cruzi, Tulahuen 2 strain in order to determine the percentage of growth inhibition (PGI) at 25 M and the IC 50 .
Compounds showing IC 50 lower than Nifurtimox (IC 50 =7.7 M) are considered active and would be considered for further testing. 42 Five compounds were selected and their unspecific cytotoxicity and genotoxicity were studied before moving on to advanced studies. Cytotoxicity was assayed in Vero cells and the IC 50 was determined from the dose-response curve. The Selectivity Index (SI) is expressed as the ratio of IC 50 in mammalian cells to IC 50 in epimastigote. The mutagenic capacity of the selected compounds was studied using the SOS/umu screening test.
The primary screening data for all compounds at 25 M are shown in Analysis of the activity data presented in Table 1 reveals that substitution of a halogen atom, on position 7 of the quinoxaline, by a cyclic amine led to a decrease of the in vitro anti-T. cruzi activity. This behavior can be observed when comparing compounds 5-9
with their parent compound A or, in general terms, comparing with compounds 1-4.
If considering mono or di-substitution by cyclic amines no conclusion can be achieved.
Di-substituted derivatives 11 and 13 showed lower PGI and higher IC 50 than their mono-substituted analogues 8 and 12. Meanwhile, derivative 10 presented very interesting data, even better than its mono-substituted analogue 5.
Regarding the type of amine substituted on position 6 and/or 7, derivatives that present a piperidine on these positions (compounds 5 and 10) stand out with IC 50 (2.6 and 2.3 M, respectively) much better than the reference drugs. When piperidine is substituted by its bioisosteres morpholine or tiomorpholine or a hydroxyl moiety is substituted on position 6, the in vitro activity of these derivatives decreases (compound 5 vs. 6-8). It can be confirmed that the most decisive structural requirement, in terms of in vitro biological activity, is the presence of electron withdrawing substituents on positions 6
and/or 7. On the other hand, substitution on position 2 of the quinoxaline ring seems not to play such an important role on biological activity as previously observed. 27, 36 This behavior can also be observed in compounds 1-4 that present the best activity data. Throughout the activity optimization process we were mindful of the importance of a good toxicological profile that would guarantee not only a potent compound but also a safe drug. Therefore and owing to the interesting in vitro trypanosomicidal activity showed by the quinoxaline derivatives, 5 compounds (3-5, 10 and 14) were selected considering their IC 50 value (compounds 3, 4 and 5) and from a structural point of view compound 10 was included due to its significant activity and in order to study the influence of the substitution of an halogen by an amine. Compound 14 was selected to evaluate the influence of the N-oxide on the toxicological profile of these derivatives.
The in vitro cytotoxicity was studied using the tetrazolium-based colorimetric assay (MTT assay) in Vero cells. The IC 50 values after 48 h of incubation are shown in Table   2 . The selective indexes (SI) were calculated as the ratio of IC 50 in Vero cells to IC 50 in T. cruzi Tulahuen 2 strain.
Moreover, the compounds were tested in the SOS/umu screening test for their genotoxicity capacity. The results obtained from the SOS/umu screening test for the selected compounds (3-5, 10, 14) with and without metabolic activation are shown in Table 2 . The evaluated doses of each compound were determined in previous toxicity studies on the test system. Regarding the unspecific cytotoxicity assay, 4 compounds (3-5 and 10) presented SI lower than 10. Compound 14 was the only one that presented a SI value higher than 25 and could be considered moderately selective. This increase in the SI is mainly due to the low non specific cytotoxicity presented by this compound which does not present a N-oxide moiety, generally related with toxic effects, in one of the nitrogens of the quinoxaline heterocycle.
The SOS/umu screening test revealed that 4 compounds (3-5 and 14) were genotoxic with and without metabolic activation and compound 10 was not genotoxic in any of the tested conditions. Interestingly, the absence of a fluoro substituent in the quinoxaline system was the only condition to loss the mutagenic capacity. From the genotoxicity point of view, this could point out the quinoxaline 10 for further studies.
According to the SI values showed in Table 2 compound 14 could be considered for further testing so that its activity against the trypomastigote and amastigote forms of T.
cruzi should be explored. However, compound 14 was genotoxic in both tested conditions, with and without metabolic activation. Therefore, none of the tested compounds will continue for further development.
In conclusion, thirteen new 1,4-di-N-oxide and two 1-N-oxide quinoxaline derivatives were synthesized and evaluated against T. cruzi identifying new derivatives with potent in vitro anti-T. cruzi activity. Ten out of the fifteen evaluated compounds resulted more active than the reference drugs Nfx and Bnz. Four of them stand out with IC 50 lower than 1.5 M. Due to the toxicity issues usually associated to this family of compounds;
unspecific cytotoxicity assay and a genotoxicity screening test were included in the very early stages of the project. Four out of the five tested compounds were mutagenic in both tested conditions. Compound 10 was not mutagenic; however, its low SI value (SI=1.7) led us to discontinue the biological studies of this family of compounds against T. cruzi. An appropriate toxicological profile study should consider not only unspecific cytotoxicity as usual but also mutagenicity issues. Including toxicological studies in the very early phases of biological evaluation would allow reducing costs and time in the overall drug discovery process.
